当前位置: 首页 >> 检索结果
4001. Expression patterns and prognostic value of key regulators associated with m7G RNA modification based on all gene expression in colon adenocarcinoma.
作者: Yuanchang Zhu.;Zeyi Zhao.;Mya Thandar.;Junhao Cheng.;Pan Chi.;Shenghui Huang.
来源: BMC Gastroenterol. 2023年23卷1期22页
N7-methylguanosine (m7G) is present in a wide variety of organisms and has important roles. m7G has been reported to be involved in multiple biological processes, and recent studies have reported that changes in RNA modifications result in tumor cellular transformation and cancer, such as colon adenocarcinoma, lung cancer, and intrahepatic cholangiocarcinoma. However, little is known about the function of the m7G in colon adenocarcinoma.
4005. Circulating Mitochondrial DNA as a Diagnostic Biomarker for Predicting Disease Severity in Patients With Acute Pancreatitis.
作者: William Yakah.;Ishani Shah.;Disha Skelton-Badlani.;Steven D Freedman.;Yury V Popov.;Sunil G Sheth.; .
来源: Gastroenterology. 2023年164卷6期1009-1011.e3页 4007. Clinical characteristics and risk factors of organ failure and death in necrotizing pancreatitis.
作者: Liqing Yu.;Fengwen Xie.;Lingyu Luo.;Yupeng Lei.;Xin Huang.;Xiaoyu Yang.;Yong Zhu.;Cong He.;Nianshuang Li.;Wenhua He.;Yin Zhu.;Nonghua Lu.;Bingjun Yu.
来源: BMC Gastroenterol. 2023年23卷1期19页
Organ failure (OF) and death are considered the most significant adverse outcomes in necrotizing pancreatitis (NP). However, there are few NP-related studies describing the clinical traits of OF and aggravated outcomes.
4008. The cost of illness analysis of inflammatory bowel disease.
作者: Majid Pakdin.;Leila Zarei.;Kamran Bagheri Lankarani.;Sulmaz Ghahramani.
来源: BMC Gastroenterol. 2023年23卷1期21页
Inflammatory bowel disease (IBD) is a chronic inflammatory condition involving individuals across all age groups. Recent data suggests the increase in the prevalence of IBD and the surge in applying the biologic drugs in which both change the cost of IBD in recent years. Comprehensive assessment of direct and indirect cost profiles associated with IBD in our area is scarce. This study aimed to determine the economic burden of IBD in Iran from a societal perspective, using cost diaries.
4009. Characteristics, clinical outcomes and patient-reported outcomes of patients with ulcerative colitis receiving tofacitinib: a real-world survey in the United States and five European countries.
作者: Alessandro Armuzzi.;Ailsa Hart.;Joseph C Cappelleri.;Nadir Mammar.;Peter Hur.;Benjamin Hoskin.;Fritha Hennessy.;Gary Milligan.;Axel Dignass.
来源: BMC Gastroenterol. 2023年23卷1期17页
To describe variations in treatment patterns, clinical outcomes, patient-reported outcomes (PRO), and physician and patient satisfaction in patients with moderate-to-severe ulcerative colitis (UC) treated with tofacitinib in a real-world setting.
4010. Protective role of circRNA CCND1 in ulcerative colitis via miR-142-5p/NCOA3 axis.
Increasing research indicates that circular RNAs (circRNAs) play critical roles in the development of ulcerative colitis (UC). This study aimed to determine the role of circRNA CCND1 in UC bio-progression, which has been shown to be downregulated in UC tissues.
4011. Expression and function of myelin expression factor 2 in hepatocellular carcinoma.
作者: Peng Zhang.;Jiang-Hua Zhao.;Lin Chen.;Zhao-Lian Bian.;Lin-Ling Ju.;Hui-Xuan Wang.;Wei-Hua Cai.
来源: BMC Gastroenterol. 2023年23卷1期20页
Hepatocellular carcinoma (HCC) is one of the most common malignant tumours in the world and has a high mortality rate. However, the pathogenesis of HCC remains unclear. This study aimed to investigate the potential biomarkers of HCC.
4013. Injectable, Drug-Eluting Nanocrystals Prevent Fibrosis and Stricture Formation In Vivo.
作者: Ling Li.;Rachel L Shapiro.;Min Kyung Joo.;Aditya Josyula.;Henry T Hsueh.;Olaya Brewer Gutierrez.;Gilad Halpert.;Venkata Akshintala.;Haiming Chen.;Samuel Curtis.;Marina Better.;Charlotte Davison.;Haijie Hu.;Jose Antonio Navarro Almario.;Steven N Steinway.;Kelton Hunt.;Rico E Del Sesto.;Jessica Izzi.;Kevan J Salimian.;Laura M Ensign.;Florin M Selaru.
来源: Gastroenterology. 2023年164卷6期937-952.e13页
Tissue fibrosis results from uncontrolled healing responses leading to excessive mesenchymal cell activation and collagen and other extracellular matrix deposition. In the gastrointestinal tract, fibrosis leads to narrowing of the lumen and stricture formation. A drug treatment to prevent fibrosis and strictures in the gastrointestinal tract would be transformational for patient care. We aimed to develop a stricture treatment with the following characteristics and components: a small molecule with strong antifibrotic effects that is delivered locally at the site of the stricture to ensure correct lesional targeting while protecting the systemic circulation, and that is formulated with sustained-release properties to act throughout the wound healing processes.
4016. The impact of intrahepatic cholestasis on pregnancy outcomes: a retrospective cohort study.
作者: Yiming Chen.;Huimin Zhang.;Wenwen Ning.;Yijie Chen.;Caihe Wen.
来源: BMC Gastroenterol. 2023年23卷1期16页
This study analyzed the pregnancy outcomes of patients with intrahepatic cholestasis of pregnancy (ICP) in Hangzhou, China.
4017. Evaluation of gut microbiota of iranian patients with celiac disease, non-celiac wheat sensitivity, and irritable bowel syndrome: are there any similarities?
作者: Kaveh Naseri.;Hossein Dabiri.;Meysam Olfatifar.;Mohammad Amin Shahrbaf.;Abbas Yadegar.;Mona Soheilian-Khorzoghi.;Amir Sadeghi.;Saeede Saadati.;Mohammad Rostami-Nejad.;Anil K Verma.;Mohammad Reza Zali.
来源: BMC Gastroenterol. 2023年23卷1期15页
Individuals with celiac disease (CD), non-celiac wheat sensitivity (NCWS), and irritable bowel syndrome (IBS), show overlapping clinical symptoms and experience gut dysbiosis. A limited number of studies so far compared the gut microbiota among these intestinal conditions. This study aimed to investigate the similarities in the gut microbiota among patients with CD, NCWS, and IBS in comparison to healthy controls (HC).
4018. Health-related quality of life and anxiety levels among patients under surveillance for intraductal papillary mucinous neoplasm.
作者: Heini Nieminen.;Risto Roine.;Ari Ristimäki.;Eila Lantto.;Norma Välimaa.;Erika Kirveskari.;Harri Sintonen.;Caj Haglund.;Hanna Seppänen.
来源: BMC Gastroenterol. 2023年23卷1期14页
Because of the premalignant nature of intraductal papillary mucinous neoplasms (IPMNs), patients should undergo surveillance as long as they remain fit for surgery. This surveillance, with imaging and laboratory tests every 6 to 12 months, is expensive and may psychologically burden patients. This study aimed to determine the effects of IPMN surveillance on patients´ health-related quality of life (HRQoL) and anxiety levels.
|